- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07605208
Programmed Intermittent Epidural Bolus Versus Continuous Epidural Infusion for Postoperative Analgesia After Total Knee Arthroplasty
Effect of Programmed Intermittent Epidural Bolus Versus Continuous Epidural Infusion on Postoperative Analgesia and Quality of Recovery After Total Knee Arthroplasty: A Prospective Randomized Double-Blind Controlled Trial
The goal of this clinical trial is to compare two different epidural analgesia delivery methods for pain control after total knee arthroplasty in adults undergoing elective surgery. The study will evaluate whether programmed intermittent epidural bolus (PIEB) provides better postoperative analgesia and recovery outcomes than continuous epidural infusion (CEI).
The main questions it aims to answer are:
Does PIEB reduce total epidural local anesthetic consumption during the first 24 postoperative hours compared with CEI? Does PIEB improve postoperative pain control and quality of recovery? Are there differences between the two methods regarding motor block, rescue analgesic requirement, patient-controlled epidural analgesia use, and adverse effects?
Researchers will compare PIEB plus patient-controlled epidural analgesia (PCEA) with CEI plus PCEA in patients undergoing total knee arthroplasty.
Participants will:
Receive combined spinal-epidural anesthesia during surgery Receive postoperative epidural analgesia using either PIEB or CEI Be evaluated for pain scores, motor block, recovery quality, epidural local anesthetic consumption, rescue analgesic requirement, and adverse events during the first 24 postoperative hours
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
Total knee arthroplasty (TKA) is one of the most commonly performed orthopedic procedures and is associated with significant postoperative pain. Inadequate pain control after TKA may delay mobilization, prolong hospitalization, impair rehabilitation, and negatively affect patient satisfaction and recovery quality. Therefore, optimizing postoperative analgesia while minimizing opioid consumption and preserving motor function is an important component of enhanced recovery after surgery (ERAS) protocols.
Epidural analgesia has been widely used for postoperative pain management for decades. Conventional continuous epidural infusion (CEI) provides stable delivery of local anesthetic but may be associated with uneven epidural spread, higher local anesthetic consumption, and increased motor blockade in some patients.
Programmed intermittent epidural bolus (PIEB) is an alternative epidural drug delivery technique in which local anesthetic is administered automatically at predefined intervals as intermittent boluses rather than as a continuous infusion. Due to the higher injection pressure and intermittent delivery pattern, PIEB may improve epidural spread and analgesic quality while reducing total local anesthetic requirements and motor block. Although PIEB has been extensively investigated in obstetric analgesia, evidence regarding its use in major orthopedic surgery remains limited.
This prospective, randomized, double-blind, parallel-group clinical trial aims to compare PIEB plus patient-controlled epidural analgesia (PCEA) with CEI plus PCEA in patients undergoing elective primary total knee arthroplasty under combined spinal-epidural anesthesia.
A total of 90 participants will be enrolled and randomized in a 1:1 ratio into two groups:
- PIEB + PCEA group
- CEI + PCEA group
Randomization will be performed using a computer-generated randomization sequence with allocation concealment through sequentially numbered opaque sealed envelopes.
All participants will receive standardized combined spinal-epidural anesthesia. Epidural catheter placement will be performed at the L2-L3 interspace using the needle-through-needle technique. Spinal anesthesia will be achieved with 12.5 mg hyperbaric bupivacaine administered intrathecally.
Postoperatively, all participants will receive epidural analgesia using the same epidural solution consisting of 0.1% bupivacaine diluted in normal saline.
In the PIEB group, epidural analgesia will be delivered as programmed intermittent epidural boluses of 6 mL every 60 minutes combined with patient-controlled epidural boluses of 6 mL with a 30-minute lockout interval.
In the CEI group, epidural analgesia will be delivered as continuous epidural infusion at 6 mL/hour combined with patient-controlled epidural boluses of 6 mL with a 30-minute lockout interval.
All participants will additionally receive standardized multimodal analgesia with scheduled paracetamol administration. Intravenous tramadol will be used as rescue analgesia when the visual analog scale (VAS) pain score is 4 or greater.
The primary outcome measure is total epidural local anesthetic consumption during the first 24 postoperative hours.
Secondary outcome measures include:
- Quality of recovery assessed using the QoR-15 questionnaire
- Motor block assessed with the modified Bromage scale
- Number of patient-controlled epidural bolus demands and delivered boluses
- Rescue analgesic consumption
- Resting and movement-related VAS pain scores
Pain scores will be assessed at postoperative 2, 4, 8, 12, and 24 hours. QoR-15 will be evaluated preoperatively and at postoperative 24 hours.
The study will be conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. Written informed consent will be obtained from all participants before enrollment.
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: AHMET R DOĞAN, M.D
- Telefoonnummer: +905427988070
- E-mail: a.ridvandogan@gmail.com
Studie Locaties
-
-
Adapazari
-
Sakarya, Adapazari, Turkije (Türkiye), 54000
- Sakarya University Training and Research Hospital, Department of Anesthesiology and Reanimation
-
Contact:
- AHMET R DOĞAN, M.D
- Telefoonnummer: +905427988070
- E-mail: a.ridvandogan@gmail.com
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Beschrijving
Inclusion Criteria:
- Adults aged 18 to 80 years
- American Society of Anesthesiologists (ASA) physical status I-III
- Scheduled for elective primary total knee arthroplasty
- Eligible for combined spinal-epidural anesthesia and postoperative epidural analgesia
- Able to understand and use patient-controlled epidural analgesia
- Provided written informed consent
Exclusion Criteria:
- Refusal to participate in the study
- Known allergy or hypersensitivity to study medications
- Body mass index (BMI) ≥ 40 kg/m²
- Body weight < 40 kg
- Severe cardiac disease, including symptomatic arrhythmia or advanced conduction abnormalities
- Coagulopathy (INR > 1.5 or platelet count < 100,000/mm³)
- Pregnancy or breastfeeding
- Revision total knee arthroplasty or emergency surgery
- Active infection at the site of regional anesthesia
- Chronic opioid use or opioid dependence
- Neurological disease or preexisting motor/sensory deficit in the lower extremities
- ASA physical status IV or V
- Requirement for intraoperative epidural local anesthetic supplementation due to inadequate spinal anesthesia
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verdrievoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: PIEB
Participants will receive postoperative epidural analgesia using programmed intermittent epidural bolus (PIEB) combined with patient-controlled epidural analgesia (PCEA).
The epidural solution will consist of 0.1% bupivacaine.
Automatic epidural boluses of 6 mL will be delivered every 60 minutes.
Patient-controlled epidural boluses of 6 mL with a 30-minute lockout interval will also be available.
|
Postoperative epidural analgesia delivered as programmed intermittent epidural boluses using 0.1% bupivacaine.
Automatic boluses of 6 mL will be administered every 60 minutes in combination with patient-controlled epidural analgesia boluses of 6 mL with a 30-minute lockout interval.
Andere namen:
|
|
Actieve vergelijker: CEI
Participants will receive postoperative epidural analgesia using continuous epidural infusion (CEI) combined with patient-controlled epidural analgesia (PCEA).
The epidural solution will consist of 0.1% bupivacaine.
Continuous epidural infusion will be administered at a rate of 6 mL/hour.
Patient-controlled epidural boluses of 6 mL with a 30-minute lockout interval will also be available.
|
Postoperative epidural analgesia delivered as continuous epidural infusion using 0.1% bupivacaine at a rate of 6 mL/hour in combination with patient-controlled epidural analgesia boluses of 6 mL with a 30-minute lockout interval.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Total epidural local anesthetic consumption during the first 24 postoperative hours
Tijdsspanne: From initiation of postoperative epidural analgesia in the post-anesthesia care unit (PACU) to postoperative 24 hours
|
Total epidural local anesthetic consumption will be calculated as the sum of automatic epidural boluses and patient-controlled epidural analgesia boluses delivered during the first 24 postoperative hours.
Total consumption will be recorded in milliliters (mL) using epidural pump records.
|
From initiation of postoperative epidural analgesia in the post-anesthesia care unit (PACU) to postoperative 24 hours
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Quality of recovery assessed with QoR-15
Tijdsspanne: Preoperative baseline and postoperative 24 hours
|
Postoperative recovery quality will be evaluated using the Quality of Recovery-15 (QoR-15) questionnaire.
The QoR-15 is a validated 15-item patient-reported outcome measure with total scores ranging from 0 to 150, where higher scores indicate better recovery.
|
Preoperative baseline and postoperative 24 hours
|
|
Number of patient-controlled epidural analgesia bolus demands and delivered boluses
Tijdsspanne: During the first 24 postoperative hours
|
The total number of patient-controlled epidural analgesia (PCEA) bolus demands and successfully delivered boluses will be recorded using epidural pump data.
|
During the first 24 postoperative hours
|
|
Rescue analgesic consumption
Tijdsspanne: During the first 24 postoperative hours
|
Rescue analgesic consumption will be assessed as the total amount of intravenous tramadol administered for breakthrough pain requiring rescue analgesia.
|
During the first 24 postoperative hours
|
|
Resting and movement-related pain scores assessed with VAS
Tijdsspanne: Postoperative 2, 4, 8, 12, and 24 hours
|
Postoperative pain intensity at rest and during movement will be assessed using a 10-point visual analog scale (VAS), where 0 indicates no pain and 10 indicates the worst imaginable pain.
|
Postoperative 2, 4, 8, 12, and 24 hours
|
|
Motor block assessed with the modified Bromage scale
Tijdsspanne: Postoperative 2 and 4 hours
|
Motor block severity will be evaluated using the modified Bromage scale, ranging from 0 to 3, where 0 indicates no motor block and 3 indicates complete motor block.
Higher scores indicate greater motor blockade.
Motor block presence will additionally be defined as a Bromage score of 1 or greater.
|
Postoperative 2 and 4 hours
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Andere studie-ID-nummers
- SEAH-OTOBOLUS-2026
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .